Chemotherapy treatments, costs of care, and survival for patients diagnosed with small cell lung cancer: A SEER-Medicare study.
Changxia ShaoJinghua HeSumesh KachrooFan JinPublished in: Cancer medicine (2019)
First-line chemotherapy was primarily platinum-based, and a plethora of different regimens was used for 2L and 3L chemotherapies. Median survival from the start of 1L chemotherapy was 9 months, with an associated health care cost of $60 000. These data highlight an unmet medical need among SCLC patients receiving systemic therapy.
Keyphrases
- healthcare
- small cell lung cancer
- locally advanced
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- palliative care
- affordable care act
- squamous cell carcinoma
- prognostic factors
- peritoneal dialysis
- radiation therapy
- rectal cancer
- mesenchymal stem cells
- social media
- chronic pain
- patient reported
- bone marrow